ArticleNanomaterials (Basel, Switzerland)2026
One-Step Immunoassay of Alpha-Fetoprotein Constructed by Silicon-Quantum-Dot-Loaded Porous Gold Nanoshells.
Article in Nanomaterials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha-fetoprotein (AFP) is widely utilized for auxiliary diagnosis of primary hepatocellular carcinoma. Therefore, the development of a facile immunosensor is essential for clinical applications. This study aims to develop a simple immunoassay for AFP detection. By incorporating silicon quantum dots (SiQDs) into etching hollow gold nanoshells (EHGNs) via precise nanomanipulation, we designed molecular probes based on SiQDs@EHGNs complex immobilized capture antibodies, which can convert the antigen/antibody binding process into fluorescent divergence signals for AFP measurement. This strategy enabled one-step fluorescence sensing for AFP detection with a linear range of 3.125-200.0 ng/mL and LOD of 0.234 ng/mL. The detection results of 15 clinical serum real samples demonstrated a 93.7% correlation with the market-accepted ECLIA method. The proposed method take advantages of simplicity and rapid response, offering a novel approach for tumor marker analysis with significant potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.